ArticleJournal of multidisciplinary healthcare2025
The Switch from Reference Biologic Medicines to Biosimilars in France: The Perspective of Patients and Prescribers on Barriers and Needs.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In France, the integration of biosimilars into medical practice in rheumatology and gastroenterology is well established. Despite a high penetration rate in hospitals, the adoption of biosimilars varies depending on the molecules. This adoption differs between new patients, for whom biosimilars are prescribed as initial biologic treatment, and those receiving these medications as part of a treatment switch from reference biologics. The objective of the COMPRENDRE study was to identify and understand the obstacles to switching from reference biologic products to their biosimilars by examining prescription practices and patient decisions. This study proposes recommendations to overcome these barriers. Patients and Methods: A total of twelve rheumatology and gastroenterology prescribers and fourteen patients with rheumatologic and gastrointestinal disorders were interviewed for qualitative insights. Subsequently, one hundred prescribing physicians and one hundred ninety patients responded to a quantitative survey to validate and explore these findings. The study was supervised by a multidisciplinary expert committee. Results: The results from the quantitative and qualitative surveys show similarities in the outcomes. In the qualitative study, 71% (10/14) of patients accepted the switch to a biosimilar. For half of them (7/14), trust in the physician-patient relationship was the main reason for acceptance. Key barriers identified by prescribers included the limited time available during consultations and patient anxiety due to their illness, both of which negatively impacted willingness to switch. In the quantitative study, 89% (89/100) prescribers reported prescribing biosimilars through switching from the reference biologic. However, only 33% (29/89) indicated that they systematically switch eligible patients. Overall, 55% (104/190) of the patients surveyed had never been offered a switch to a biosimilar. Conclusion: Switching from a reference biologic to biosimilars is hampered by several factors, including the lack of systemic proposals in the practice of prescribers as well as the lack of information given to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.